Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings
CNBC Earnings
Barrons Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

Stocktwits
MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-

Allogene Therapeutics, Inc. Common Stock | ALLO

Daily Technical Analysis of Allogene Therapeutics, Inc. Common Stock

Allogene Therapeutics moved up less than 1% today. The market isn't being very decisive in its valuation of asset.

Allogene Therapeutics doesn't seem to be at a very clear reversal point in either direction. Allogene Therapeutics has been drifting up over the last few months, we'll see if it has the energy to keep moving in the right direction. ALLO might find some support at the 2.53 level, buyers might push the price back up from here. But it's not very clear what will happen.


Last analyzed on 2024-03-17

Analyst Ratings for Allogene Therapeutics By Price Target And Rating

Overall, the analysts have a more negative view on Allogene Therapeutics but it's not a very strong negative. The current Analysts Sentiment Score is -12.02. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. HC Wainwright announced a lowering of their price target to $10.00 from $12.00 on 2024-01-19. JMP Securities reiterated a rating of Outperform on 2024-01-05. Guggenheim downgraded from Buy to Neutral on 2024-01-05. Citigroup initiated a rating of Buy on 2023-12-08 and provided a price target of $7.00. JPMorgan Chase & Co. provided a price target decease of -18.18% to $9.00 from $11.00 on 2023-09-25. Oppenheimer reiterated a rating of Outperform on 2023-08-03 and added a price target of $28.00. Truist Financial decided to move down their price target on 2023-07-12 to $18.00 which is a -10% decrease. On 2023-05-04 Stifel Nicolaus lowered their price target by -6.25% to $7.50. EF Hutton Acquisition Co. announced that they are reiterating a rating of Buy on 2023-04-17 and they set their price target at $15.00. William Blair reiterated a rating of Outperform on 2023-03-22.

Company Ratings Score ?
Composite analyst sentiment score
Positive Ratings Negative Ratings Boost Price Target Lower Price Target
ALLO-12.0239.59-79.1138.4-22.91

Earnings Per Share (EPS) Estimates By Year and Quarter

(updated 2024-02-27)
Company YOY Growth Score (typical -20 to +20) Revision Directions (-6 to +6)
ALLO13.43-1.30

Short interest for Allogene Therapeutics

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Company Short Score (typical 1-15) ?
We take into account several different measures and attributes of short interest to create a composite sentiment score. typical range (0 - 30)
Short Interest Days to Cover Rate of Change Shares Short
ALLO28.35%32.2227.52434030000

Social Sentiment for Allogene Therapeutics

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.

Ticker Social Sentiment(1-10)
ALLO

Companies with the highest correlation to Allogene Therapeutics

Company Score 1 Day% 5 Day 1 Month 3 Month 6 Month 1 Year RSI 3mo S-momo ? 6mo S-momo 1yr S-momo Resistance ? Support Demark Sell ? Demark Buy Short Interest Score
CRSP | CRISPR Therapeutics AG1.03-2.02-4.01-17.929.8845.8556.761257.6450.1337.40-2101.92-9760.98015015.3247
DNLI | Denali Therapeutics Inc. 1.02-0.055.81-0.482.12-0.95-10.0944-10.54-23.64-26.73-17158.84-1907.180011.2371
SDGR | Schrodinger, Inc. Common 0.981.280.750.60-16.78-1.509.5041-9.59-8.05-8.61-7848.89-3412.90009.02067

Top 3 correlating companies

See full charts for all peers

Sentiment Score

How to use: use the research links to research the asset. Then simply type in a score for each category between (01, 02, 03, 04, 05). 05 being the most bullish and 01 being the most bearish. It will automatically calculate the average and combine it with the technical score to create an overall score to rank prospects by. You can also type notes into each field.

Earnings Estimates
Analyst Rating
Price Targets
Short Interest
Financials
Options Sentiment
Institutional Ownership
Social Sentiment
Fidelity Summary
Overall Summary Notes
Calculated Sentiment Sum

Score Sum
(1-45)

/

Average
(1-5)

+

Pattern Rank
(1-5)

=

Total Score
(1-10)

Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-